Certain approaches while choosing the strategy of Covid-19 pathogenetic therapy and immunoprophylaxis
prev
next
prev
next
Author(s)
Author(s)
Certain approaches while choosing the strategy of Covid-19 pathogenetic therapy and immunoprophylaxis Arto Zilfyan
This report provides the authors’ viewpoints on the prospects of carrying out several therapeutic and prophylactic measures aimed at least improving the health of patients suffering from COVID-19.
In addition, the authors have some doubts (fears) of using vaccines, the production of which is currently involved in well-known commercial pharmaceutical enterprises and scientific institutions of a number of leading countries of the world. At the same time, the authors place special emphasis on the scientific and technological process of vaccine production, when, as “initial raw materials”, in each specific case, are used separate variations from the general structure of viruses pathogenic for humans, including SARS-CoV-19, integral killed coronaviruses, crossreactive antibodies to SARS-CoV-19, which are obtained as a result of appropriate scientific and technological preparation of other viruses (for example, arboviruses).
How effective these vaccines will turn out to be is a matter of time, primarily due to their
“approbation” on a wide contingent of people of different nationalities and living in different regions of the world.
According to the authors, the effectiveness of vaccines in many respects depends on the intensity degree and relatively long-term binding of specific antibodies to viruses, as well as on the results of active vaccination, especially since coronaviruses are characterized by a very wide variability of antigenic determinants, represented, in particular, by at least six antigen receptors.
The authors’ doubts in this aspect served as a prerequisite for recommending new scientific and methodological approaches for COVID-19 treatment, based on the principles of suppressing the functional activity of SARS-CoV-2, both at the initial stages of binding the virus to the target cell membrane of the infected organism, and in the processes of their endocytosis, translation, replication and exocytosis of daughter viruses.
A detailed analysis of modern informative literary sources, as well as their own research, according to the authors, can serve as a real prerequisite for including α difluoromethylornithine in the general treatment regimen for COVID-19 patients, a drug that selectively inhibits the initial stages of polyamine synthesis, thereby leading to significant suppression of SARS-CoV-2 biological activity in the infected organism.
DOI: https://ysmu.am/v2/wp-content/uploads/2023/05/27fdbd6b-1.pdf The New Armenian Medical Journal Vol.15 (2021), Nо 1 4-18
